Philippe Duchateau - Cellectis Chief Scientific Officer
| ALCLS Stock | EUR 1.54 0.02 1.32% |
Executive
Dr. Philippe Duchateau has served as Chief Scientific Officer and Member of Executive Committee at Cellectis SA since January 30, 2012. He joined the Company in 2001 and he served as Head of Research Department from 2004. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur, he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco within the Cardiovascular Research Institute. He is coinventor of numerous patents in the field of nucleases and gene editing and coauthor on more than 50 scientific publications and coeditor of one book entitled Sitedirected Insertion of Transgenes. since 2012.
| Age | 60 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 33 1 81 69 16 00 |
| Web | https://www.cellectis.com |
Cellectis Management Efficiency
The company has return on total asset (ROA) of (0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | EXECUTIVE Age | ||
| Olivier Martinez | Adocia | 46 | |
| Wence Agbotounou | DBV Technologies SA | N/A | |
| Hugh Sampson | DBV Technologies SA | 70 | |
| Richard Charvet | Adocia | N/A | |
| Martin Gaudier | Adocia | N/A | |
| Jose Correia | Adocia | N/A | |
| Gregory Meiffren | Adocia | N/A | |
| Bertrand Alluis | Adocia | N/A | |
| Pharis Mohideen | DBV Technologies SA | 58 | |
| Dominique Takizawa | Adocia | 60 | |
| David Duracher | Adocia | N/A | |
Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 |
Cellectis Leadership Team
Elected by the shareholders, the Cellectis' board of directors comprises two types of representatives: Cellectis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellectis. The board's role is to monitor Cellectis' management team and ensure that shareholders' interests are well served. Cellectis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellectis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andre Choulika, Chairman of the Board and CEO, Member of the Executive Committee | ||
| MarieBleuenn Terrier, General Counsel, Member of the Executive Committee | ||
| Dr MBA, Chief Officer | ||
| David Sourdive, Co-Founder, Executive VP of Corporate Devel. and Director | ||
| Valerie Cros, Principal Officer | ||
| Kyung NamWortman, Ex Officer | ||
| Philippe Duchateau, Chief Scientific Officer | ||
| Pascalyne Wilson, Director Communications | ||
| Jean Epinat, Chief Officer | ||
| MSc MSc, Chief Officer |
Cellectis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cellectis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 78.42 M | |||
| Shares Outstanding | 55.59 M | |||
| Shares Owned By Institutions | 21.25 % | |||
| Price To Earning | (14.84) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 4.34 X | |||
| Revenue | 57.29 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.